MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

205.41
-3.47
-1.66%
After Hours: 203.72 -1.69 -0.82% 17:43 04/03 EDT
OPEN
207.43
PREV CLOSE
208.88
HIGH
209.75
LOW
203.03
VOLUME
2.28M
TURNOVER
--
52 WEEK HIGH
244.99
52 WEEK LOW
166.30
MARKET CAP
121.15B
P/E (TTM)
15.95
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 28 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AMGN stock price target is 243.21 with a high estimate of 285.00 and a low estimate of 185.00.

EPS

AMGN News

More
  • Week 15 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
  • Seeking Alpha - Article · 1h ago
  • Why Gilead Sciences Is the Hottest Stock to Buy Today
  • MotleyFool.com · 11h ago
  • Video: 4 Large-Cap Stocks With Strong Buffett-Munger Characteristics
  • GuruFocus.com · 22h ago
  • Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
  • Zacks · 1d ago

Industry

Pharmaceuticals
-0.14%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About AMGN

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
More

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.